# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Howard Hughes (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML006-SYN
- Date: 2026-05-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Anselm Garrity-Moyo, MD
- Calendar frame: modern shifted

## What we are working on

- He wants to get back to full days of work without hours of washing and checking, and without other people seeing his rituals **S**
- He is afraid that without codeine the pain from the crash will stop him working **S**
- He wants his privacy protected and nothing about his care known outside the clinic **S**

## Your goals

- Y-BOCS down by at least 35 percent (response) within six months. Target: 2026-10-05. Recorded outcome: Y-BOCS 28 at intake, 14 at twenty-two weeks (a 50 percent fall); washing and checking about one hour a day. **S**
- Stop codeine and stay on buprenorphine with no use of other opioids. Target: 2026-10-05. Recorded outcome: Codeine stopped at one week; all urine tests positive for buprenorphine and negative for other opioids. **S**
- Pain that lets him work and sleep: PEG at or below 4. Target: 2026-10-05. Recorded outcome: PEG 6.7 at intake to 4.0 at twenty-two weeks. **S**
- Regain weight to at least 76 kg with regular meals. Target: 2026-10-05. Recorded outcome: 72.0 kg at intake to 76.2 kg; three meals a day, including food prepared by his cook. **S**
- Follow conversation in meetings with hearing aids. Target: 2026-10-05. Recorded outcome: Hearing aids fitted at ten weeks and worn every day. **S**
- Staff stop carrying out rituals for him, step by step, by his own plan. Target: 2026-10-05. Recorded outcome: Tissue-wrapping and the hand-washing rule for staff stopped; food preparation rules relaxed; visitors no longer screened for illness. **S**

## What we agreed to do

- Psychiatry consultation to confirm the diagnosis, advise on an SSRI at OCD doses with buprenorphine, plan exposure and response prevention, and advise on how his staff can stop carrying out rituals for him. Guideline: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007); Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013); Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005) **S**
- Opioid review under the CDC 2022 guideline: benefits and harms reviewed with him, a prescription drug monitoring program check before every controlled-substance prescription, urine drug testing with consent and explained as part of care, one prescriber and one pharmacy, a nonjudgmental DSM-5-TR assessment for opioid use disorder, and no abrupt stop of codeine. Guideline: CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022); Prescription Drug Monitoring Programs (PDMPs) (2026) **S**
- Buprenorphine with naloxone for opioid use disorder and pain: induction in the clinic at one week after about 20 hours without codeine, then 8 mg twice daily, dispensed weekly at first; naloxone nasal spray at home; no benzodiazepines; leftover codeine to a pharmacy take-back. Guideline: CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020) **S**
- Pain after major trauma: scheduled acetaminophen up to 3,000 mg a day, physical therapy for the chest wall, left shoulder and low back, graded activity, sleep, and pain coping skills woven into his therapy; no NSAID long term. Guideline: CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022) **S**
- OCD treatment: exposure and response prevention with a psychologist, weekly 90-minute sessions with home practice, then twice weekly; sertraline from 50 mg, raised every four to six weeks as tolerated toward 200 mg; response judged by the Y-BOCS at each visit; augmentation with a low-dose antipsychotic (aripiprazole or risperidone) or a switch to clomipramine considered only if the response is poor after 8 to 12 weeks at the highest tolerated dose. Guideline: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007); Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013); Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005) **S**
- Accommodation by staff: with his written consent, his assistant joins two therapy sessions; staff stop carrying out rituals for him in planned steps that follow his exposure hierarchy, offer support instead of reassurance, and are not asked to report on him. Guideline: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007); Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005) **S**
- Safety: a structured safety assessment, a written safety plan, the 988 Suicide & Crisis Lifeline in his phone, means safety for opioids, and safety review at every visit. Guideline: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Hearing: audiometry, then hearing aids and a remote microphone if hearing loss is confirmed; hearing protection when flying and in the factory. Guideline: Hearing loss in adults: assessment and management (NG98) (2018) **S**
- Nutrition and weight: a dietitian visit, three meals a day built into his exposure plan (food made by his cook, then food from a restaurant), weight at each visit, albumin at baseline and follow-up; no supplements needed. Guideline: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007) **S**
- Kidney health: creatinine, eGFR and urine albumin at baseline and a metabolic panel at follow-up while on scheduled acetaminophen and any new medicine; acetaminophen kept at or below 3,000 mg a day; no long-term NSAID. Guideline: CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022) **S**
- Privacy: care documented in the clinic record only; letters about his health go only to people he names. Guideline: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007) **S**

## Follow-up

- 2026-05-04: Establishing primary care ten months after a plane crash: contamination fears with washing and avoidance, chronic pain on long-term codeine, an opioid review, hearing, weight, kidney health and safety **S**
- 2026-05-11: One-week review, seen the same day by psychiatry: the diagnosis of OCD, an SSRI, exposure and response prevention, and starting buprenorphine **S**
- 2026-06-08: Five-week review: OCD treatment, buprenorphine, pain, the audiogram and weight **S**
- 2026-07-13: Ten-week review: sertraline to an OCD dose, exposure therapy and his staff's part in it, hearing aids and pain **S**
- 2026-09-14: Periodic adult preventive visit **S**
- 2026-10-05: Twenty-two-week review: response of OCD, buprenorphine maintenance, pain, weight and laboratory checks **S**

This teaching document does not replace care from a qualified clinician.
